Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Regen BioPharma (RGBPP) over the last 10 years, with Q4 2025 value amounting to $4.3 million.

  • Regen BioPharma's Total Non-Current Liabilities rose 738.89% to $4.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year increase of 738.89%. This contributed to the annual value of $4.5 million for FY2025, which is 1262.66% up from last year.
  • Per Regen BioPharma's latest filing, its Total Non-Current Liabilities stood at $4.3 million for Q4 2025, which was up 738.89% from $4.5 million recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Total Non-Current Liabilities ranged from a high of $7.8 million in Q3 2021 and a low of $143685.0 during Q1 2024
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $4.2 million (2025), whereas its average is $4.2 million.
  • Per our database at Business Quant, Regen BioPharma's Total Non-Current Liabilities plummeted by 9634.98% in 2024 and then soared by 280687.06% in 2025.
  • Over the past 5 years, Regen BioPharma's Total Non-Current Liabilities (Quarter) stood at $6.6 million in 2021, then fell by 17.95% to $5.4 million in 2022, then crashed by 97.14% to $153981.0 in 2023, then skyrocketed by 2530.42% to $4.1 million in 2024, then rose by 7.39% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q4 2025, $4.5 million for Q3 2025, and $4.2 million during Q2 2025.